Beta Receptor Blockade Potentiates the Antiarrhythmic Actions of d‐Sotalol on Reentrant Ventricular Tachycardia in a Canine Model of Myocardial Infarction

Introduction: The importance of beta receptor blockade for the antiarrhythmic action of sotalol has not been completely elucidated. We determined how beta receptor blockade interacts with the effects of potassium channel blockade on reentrant circuits.

[1]  L. Opie,et al.  Sotalol , 2021, Reactions Weekly.

[2]  K. Ellenbogen,et al.  Variation of Spectral Power Immediately Prior to Spontaneous Onset of Ventricular Tachycardia/Ventricular Fibrillation in Implantable Cardioverter Defibrillator Patients , 1999, Journal of cardiovascular electrophysiology.

[3]  N S Peters,et al.  Characteristics of the temporal and spatial excitable gap in anisotropic reentrant circuits causing sustained ventricular tachycardia. , 1998, Circulation research.

[4]  N S Peters,et al.  Mechanisms causing sustained ventricular tachycardia with multiple QRS morphologies: results of mapping studies in the infarcted canine heart. , 1997, Circulation.

[5]  D. Shindler,et al.  A Pharmacokinetic—Pharmacodynamic Model of d‐Sotalol Q‐Tc Prolongation During Intravenous Administration to Healthy Subjects , 1997, Journal of clinical pharmacology.

[6]  J. Brachmann,et al.  Differential effects of d-sotalol on normal and infarcted myocardium: an experimental study using epicardial mapping. , 1997, Cardiovascular research.

[7]  M. Reiter,et al.  Sotalol for ventricular tachyarrhythmias: beta-blocking and class III contributions, and relative efficacy versus class I drugs after prior drug failure. ESVEM Investigators. Electrophysiologic Study Versus Electrocardiographic Monitoring. , 1997, The American journal of cardiology.

[8]  K. Eto,et al.  Effects of dofetilide, a class III antiarrhythmic drug, on various ventricular arrhythmias in dogs. , 1996, Journal of cardiovascular pharmacology.

[9]  Bertram Pitt,et al.  Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction , 1996, The Lancet.

[10]  S Nattel,et al.  Evidence for two components of delayed rectifier K+ current in human ventricular myocytes. , 1996, Circulation research.

[11]  L. H. Frame,et al.  d-Sotalol terminates reentry by two mechanisms with different dependence on the duration of the excitable gap. , 1996, The Journal of pharmacology and experimental therapeutics.

[12]  P. Sager,et al.  Frequency‐Dependent Electrophysiologic Effects of d,1‐Sotalol and Quinidine and Modulation by Beta‐Adrenergic Stimulation , 1996, Journal of cardiovascular electrophysiology.

[13]  S. Hohnloser,et al.  Efficacy and safety of d-sotalol, a pure class III antiarrhythmic compound, in patients with symptomatic complex ventricular ectopy. Results of a multicenter, randomized, double-blind, placebo-controlled dose-finding study. The d-Sotalol PVC Study Group. , 1995, Circulation.

[14]  S. Priori,et al.  Sympathetic activation, ventricular repolarization and Ikr blockade: implications for the antifibrillatory efficacy of potassium channel blocking agents. , 1995, Journal of the American College of Cardiology.

[15]  J. Coromilas,et al.  Electrophysiological effects of flecainide on anisotropic conduction and reentry in infarcted canine hearts. , 1995, Circulation.

[16]  C. Antzelevitch,et al.  Characteristics of the delayed rectifier current (IKr and IKs) in canine ventricular epicardial, midmyocardial, and endocardial myocytes. A weaker IKs contributes to the longer action potential of the M cell. , 1995, Circulation research.

[17]  CharlesAntzelevitch,et al.  Characteristics of the Delayed Rectifier Current (IKr and IKs) in Canine Ventricular Epicardial, Midmyocardial, and Endocardial Myocytes , 1995 .

[18]  J. Maylie,et al.  Beta-adrenergic blocking property of dl-sotalol maintains class III efficacy in guinea pig ventricular muscle after isoproterenol. , 1995, Circulation.

[19]  M. Allessie,et al.  Effects of Heptanol, Class Ic, and Class III Drugs on Reentrant Ventricular Tachycardia: Importance of the Excitable Gap for the Inducibility of Double‐Wave Reentry , 1994, Circulation.

[20]  J. Mason.  A Comparison of Seven Antiarrhythmic Drugs in Patients with Ventricular Tachyarrhythmias , 1994 .

[21]  J. Brachmann,et al.  Acute and chronic antiarrhythmic efficacy of d-sotalol in patients with sustained ventricular tachyarrhythmias. , 1993, European heart journal.

[22]  J. Mason.  A comparison of seven antiarrhythmic drugs in patients with ventricular tachyarrhythmias. Electrophysiologic Study versus Electrocardiographic Monitoring Investigators. , 1993, The New England journal of medicine.

[23]  E. Williams.  Classifying Antiarrhythmic Actions: By Facts or Speculation , 1992, Journal of clinical pharmacology.

[24]  H. Huikuri,et al.  Frequency Dependent Effects of d‐Sotalol and Amiodarone on the Action Potential Duration of the Human Right Ventricle , 1992, Pacing and clinical electrophysiology : PACE.

[25]  R. Freedman,et al.  Effects of sotalol on the signal-averaged electrocardiogram in patients with sustained ventricular tachycardia: relation to suppression of inducibility and changes in tachycardia cycle length. , 1992, Journal of the American College of Cardiology.

[26]  G. Steinbeck,et al.  A comparison of electrophysiologically guided antiarrhythmic drug therapy with beta-blocker therapy in patients with symptomatic, sustained ventricular tachyarrhythmias. , 1992, The New England journal of medicine.

[27]  G. Butrous,et al.  Adrenergic Effects on Reentrant Ventricular Rhythms in Subacute Myocardial Infarction , 1992, Circulation.

[28]  D. Roden,et al.  A mechanism of D-(+)-sotalol effects on heart rate not related to beta-adrenoceptor antagonism. , 1990, British journal of clinical pharmacology.

[29]  P. Corr,et al.  Beta-adrenergic-mediated influences on microscopic conduction in epicardial regions overlying infarcted myocardium. , 1990, Circulation research.

[30]  M. Sanguinetti,et al.  Two components of cardiac delayed rectifier K+ current. Differential sensitivity to block by class III antiarrhythmic agents , 1990, The Journal of general physiology.

[31]  Y. Nakamura,et al.  Electrophysiologic effects of E-4031, a class III antiarrhythmic agent, on re-entrant ventricular arrhythmias in a canine 7-day-old myocardial infarction model. , 1990, The Journal of pharmacology and experimental therapeutics.

[32]  P. Tchou,et al.  Isoproterenol reversal of antiarrhythmic effects in patients with inducible sustained ventricular tachyarrhythmias. , 1989, Journal of the American College of Cardiology.

[33]  W. Mello.  Effect of isoproterenol and 3-isobutyl-1-methylxanthine on junctional conductance in heart cell pairs , 1989 .

[34]  M. Allessie,et al.  Influences of anisotropic tissue structure on reentrant circuits in the epicardial border zone of subacute canine infarcts. , 1988, Circulation research.

[35]  C. Reilly,et al.  Ultra‐short‐acting beta‐blockade: A comparison with conventional beta‐blockade , 1985, Clinical pharmacology and therapeutics.

[36]  P. Ursell,et al.  Electrophysiologic and anatomic basis for fractionated electrograms recorded from healed myocardial infarcts. , 1985, Circulation.

[37]  B. Lucchesi,et al.  Prevention of ventricular fibrillation by dextrorotatory sotalol in a conscious canine model of sudden coronary death. , 1985, American heart journal.

[38]  R. Peto,et al.  Beta blockade during and after myocardial infarction: an overview of the randomized trials. , 1985, Progress in cardiovascular diseases.

[39]  J. Brachmann,et al.  Action of sotalol on potential reentrant pathways and ventricular tachyarrhythmias in conscious dogs in the late postmyocardial infarction phase. , 1983, Circulation.

[40]  H. Karagueuzian,et al.  Protracted ventricular tachcardia induced by premature stimulation of the canine heart after coronary artery occlusion and reperfusion. , 1979, Circulation research.

[41]  H. Karagueuzian,et al.  Protracted Ventricular Tachycardia Induced by Premature Stimulation of the Canine Heart after Coronary Artery Occlusion and Reperfusion , 1979 .

[42]  C. Mewis,et al.  Suppression of sustained ventricular tachyarrhythmias: a comparison of d,l-sotalol with no antiarrhythmic drug treatment. , 1999, Journal of the American College of Cardiology.

[43]  S. Hohnloser,et al.  Efficacy and safety of d-sotalol, a pure class III antiarrhythmic compound, in patients with symptomatic complex ventricular ectopy. Results of a multicenter, randomized, double-blind, placebo-controlled dose-finding study. The d-Sotalol PVC Study Group. , 1995, Circulation.

[44]  S. Hohnloser,et al.  Drug therapy : Sotalol , 1994 .

[45]  E. V. Vaughan Williams.  Classifying antiarrhythmic actions: by facts or speculation. , 1992, Journal of clinical pharmacology.

[46]  M. Sanguinetti,et al.  Isoproterenol antagonizes prolongation of refractory period by the class III antiarrhythmic agent E-4031 in guinea pig myocytes. Mechanism of action. , 1991, Circulation research.

[47]  P. Corr,et al.  Antiarrhythmic efficacy of a new class III agent, UK-68,798, during chronic myocardial infarction: evaluation using three-dimensional mapping. , 1991, The Journal of pharmacology and experimental therapeutics.

[48]  R. Lux,et al.  Correlation between in vivo transmembrane action potential durations and activation-recovery intervals from electrograms. Effects of interventions that alter repolarization time. , 1990, Circulation.

[49]  W. D. De Mello.  Effect of isoproterenol and 3-isobutyl-1-methylxanthine on junctional conductance in heart cell pairs. , 1989, Biochimica et biophysica acta.